Skip links

Long-acting sstr2 antagonists and Pretargeted Alpha Therapy: a super combination for safer and more efficient treatment of neuroendocrine tumors

Project summary

Radionuclides are promising molecules in cancer treatment. However, due to side effects on healthy tissue, it is not always possible to administer a sufficiently high dose. The aim of this research is to enable a more effective treatment of neuroendocrine tumors with radionuclides.


If this research is successful, the step towards a patient study can be made. The researchers expect to be able to tackle some practical problems surrounding PRRT with this new method. The new method can help ensure that a higher dose of radioactive molecules reaches the tumor more efficiently and thus kills the cells with fewer side effects. That could make healing possible, or at least survive longer with a better quality of life.

More detailed information

Principal Investigator:

dr. Yann Seimbille

Role Erasmus MC:



Radiologie & Nucleaire Geneeskunde

Project website:

Funding Agency: